What is Leerink Partnrs’ Estimate for BOLT Q1 Earnings?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Research analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for Bolt Biotherapeutics in a research report issued on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings per share of ($0.36) for the quarter. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS and Q4 2026 earnings at ($0.16) EPS.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Tuesday. Stifel Nicolaus lowered their price objective on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a report on Tuesday. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bolt Biotherapeutics presently has an average rating of “Hold” and an average target price of $1.13.

Bolt Biotherapeutics Stock Performance

NASDAQ:BOLT opened at $0.43 on Thursday. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm’s fifty day simple moving average is $0.47 and its 200 day simple moving average is $0.55. The stock has a market cap of $16.29 million, a P/E ratio of -0.25 and a beta of 0.94. Bolt Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $1.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.79 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%.

Institutional Trading of Bolt Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BOLT. FMR LLC increased its stake in shares of Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares in the last quarter. Millennium Management LLC bought a new stake in Bolt Biotherapeutics in the fourth quarter worth $25,000. Squarepoint Ops LLC bought a new stake in Bolt Biotherapeutics in the fourth quarter worth $26,000. Velan Capital Investment Management LP purchased a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth $27,000. Finally, Citadel Advisors LLC bought a new position in shares of Bolt Biotherapeutics during the fourth quarter valued at $42,000. 86.70% of the stock is owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.